肾衰养真胶囊对慢性肾衰竭大鼠脂代谢紊乱的影响

摘要/Abstract

摘要： 目的观察肾衰养真胶囊对慢性肾衰竭(CRF)大鼠脂代谢紊乱的治疗效果并探讨其可能机制。方法对50 只SD 雄性大鼠采用5/6 肾切除法制作CRF大鼠模型,随机分为空白模型对照组、吉非罗齐治疗组及肾衰养真胶囊高、中、低剂量治疗组;另设正常对照组。于喂药4周后,观察各组脂谱及脂蛋白谱,并用反转录聚合酶链式反应(RT-PCR)法检测心肌脂蛋白脂酶信使RNA(LPLmRNA)的表达。结果两药均能降低总胆固醇、甘油三酯、低密度脂蛋白胆固醇,升高高密度脂蛋白胆固醇,同时LPLmRNA 表达上调,肾衰养真胶囊各治疗组之间无差异。结论肾衰养真胶囊可通过促进LPLmRNA 转录而调节血脂水平,改善脂蛋白谱,这可能是肾衰养真胶囊改善CRF大鼠脂代谢紊乱的机制之一。

Abstract: Objective To investigate the therapeutic effect of Shenshuai Yangzhen capsule, a preparation of traditional Chinese medicine, on lipid metabolism disorder in rats with chronic renal failure (CRF) and explore its mechanism. Methods Fifty male SD rats received 5/6 nephrectomy for preparation of CRF models and were randomized into CRF group, gemfibrozil group, high-, moderate- and low-dose Shenshuai Yangzhen groups, and normal control group. After 4-week treatment as indicated, myocardial lipoprotein lipase messenger RNA (LPL mRNA) level were measured by RT-PCR in rats with surgically induced renal failure (two-stage subtotal nephrectomy). The blood lipid parameters in CRF rats were also determined. Results Compared with those in the CRF group, the plasma total cholesterol, triglyceride, low-density lipoprotein cholesterol and very-low-density lipoprotein cholesterol concentrations in the treatment groups were significantly lower with substantially elevated plasma high-density lipoprotein cholesterol and LPL gene expression. No significant differences were noted between different dose groups of Shenshuai Yangzhen. Conclusion Shenshuai Yangzhen capsule can regulate blood lipid levels in rats with renal insufficiency possibly by enhancing LPL gene expression.

中图分类号:

R285.5

李玉明, 魏连波, 袁钢, 马志刚, 黄琳. 肾衰养真胶囊对慢性肾衰竭大鼠脂代谢紊乱的影响[J]. 南方医科大学学报, 2004, 24(05): 549-552.

LI Yu-ming, WEI Lian-bo, YUAN Gang, MA Zhi-gang, HUANG Lin. Effects of Shenshuai Yangzhen capsule on lipid metabolism disorder in rats with chronic renal failure[J]. Journal of Southern Medical University, 2004, 24(05): 549-552.

参考文献

[1] Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis[J]. J Lab Clin Med, 1997, 130(4): 387.
[2] 焦玉清,卢思广,董晨,等.实验性肾病综合征大鼠脂蛋白脂酶活力及基因表达的改变[J].徐州医学院学报(Acta Acade Med Xuzhou),2001,21(4):329-32
[3] 李明旭,张志勇,余永武.肾脏疾病血脂动态观察及干预治疗效果比较[J].天津医药(Tianjin Med J),2003,8(8):527-9
[4] 施新猷.现代医学实验动物学[M].北京:人民军医出版社,2000.476-7.
[5] 陈奇.中药药理实验[M].贵阳:贵州人民出版社,1988.33-5.
[6] Brault D, Noe L, Etienne J, et al. Sequence of rat lipoprotein lipasecDNA[J]. Gene, 1992, 121(2): 237-46.
[7] Nudel U, Zakut R, Shani M, et al. The nucleotide sequence of the rat cytoplasmic beta-actin gene [J]. Nucleic Acdis Res, 1983, 11 (6):1759-71.
[8] 梁玉环,关广聚,吴涛.脂质代谢紊乱对慢性肾衰患者肾功能的影响[J].山东医药,2002,42(9):38-9.
[9] 张辰珠,于青,王玉新.终末期肾衰患者脂代谢紊乱及相关因素分析[J].肾脏病与透析肾移植杂志(J Nephrol Dial Transplant),2003,1(2):157-9.
[10] 何成文,叶志斌,袁伟杰,等.持续不卧床腹膜透析患者血脂的动态观察[J].中国血液净化(Chin J Blood Purif),2001,2(2):131-3.
[11] 张国华,张训.尿毒症病人动脉粥样硬化的研究进展[J].中华内科杂志(Chin JIntern Med),2000,39(11):781-3.
[12] 袁伟杰,湛冯岚,张小瑛,等低分子肝素对血液透析患者脂质代谢影响的临床研究[J].中华肾脏病杂志(Chin J Nephrol),2000,16(3):152-4.
[13] Keane WF. Lipid and kidney[J]. Kidney Int, 1994, 46: 910.
[14] McGregor D, Shand B, Lynn K. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-staGe renal disease[J]. Nephron, 2000, 85(3): 215-20.
[15] 曾昭龙,张暋,李小敏,等.正脂丸治疗高脂血症疗效观察[J].第一军医大学学报(J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao),1999,19(4S):29-3.
[16] 柯凌.大黄的药理及其在肾脏病中的运用[J].中国中西医结合杂志(Chin J Integr Tradit West Med),2001,2(6):347-8.
[17] 张翥,方敬爱,叶任高.中药的肾保护与肾毒性[J].中国中西医结合肾病杂志(Zhong Guo Zhong Xi Yi Jie He Shen Bing Za Zhi),2001,2(9):552-6.
[18] 刘杰,陈小珍,阙斌,等.益肾汤对慢性肾功能衰竭大鼠血脂及氧自由基的影响[J].河北中医(Hebei J TCM),2001,23(2):150-1.
[19] 张颍娟,周启林.老年糖尿病肾病中药治疗前后血脂、过氧化物歧化酶的变化[J].第一军医大学学报(J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao),2001,21(1):42-3.
[20] Amadottir M. Pathogenesis of dyslipoproteinemia in renal in sufficiency: the role of lipoprotein lipase and hepatic lipase [J]. Scand J Clin Lab Invest, 1997, 57: 15.
[21] 李宁军,李惊子,辛岗,等.黄芪当归合剂对肾病综合征大鼠脂蛋白脂酶和卵磷脂胆固醇酰基转移酶的影响[J].中国中西医结合杂志(Chin JIntegr Tradit West Med),1999,19(8):484-6.